Investigating potential for an oral treatment in diabetic retinopathy  

Breye Therapeutics, a clinical-stage biopharmaceutical company developing novel oral therapies for retinal vascular diseases within ophthalmology, has started a Phase Ib/IIa clinical trial to investigate danegaptide, following oral administration, in patients suffering from diabetic macular oedema (DMO). 

Breye is developing novel, oral ophthalmology drugs fordiabetic retinopathy (DR) or age-related macular degeneration (AMD). While there has been successful development of intravitreally administered products for patients with late-stage disease, treatment options are currently limited for patients in the early or moderate stages.  

As an oral therapy, danegaptide targets the core pathological events in DR, including cell-cell uncoupling, apoptotic vascular cell death and vascular leakage, at earlier stages of disease progression.  

The study’s design is a multicentre, open-label, dose-escalating Phase Ib/IIa study to assess the safety, tolerability, pharmacokinetics (PK), and early signs of biological activity following oral administration of danegaptide in participants diagnosed with DMO. 

Support for danegapitide’s potential  

With safety data derived from over 500 clinical trial participants, robust toxicology data, and strong non-clinical in vitro and in vivo efficacy results, there is strong support for danegaptide’s potential to address the clinical core ocular pathologies of vascular leakage and capillary breakdown. The positive effects of treating these pathologies have been clinically validated.  

Ulrik Mouritzen, Chief Executive Officer of Breye Therapeutics, said: “The launch of the Phase Ib/IIa clinical trial for danegaptide represents a significant milestone towards realising our mission of developing more effective, globally accessible orally administered treatment solutions for patients at risk of vision loss and blindness. The burden on patients with diabetic retinopathy is significant and those who experience vision loss and blindness face threats to their physical and mental health and overall quality of life. At Breye, we are committed to help treat the disease earlier by offering effective oral therapies, to patients who currently have limited or no treatment options.”  

Professor Carl Regillo, Director of Retina Service of Wills Eye Hospital and Professor of Ophthalmology at Thomas Jefferson University in Philadelphia, Member of the Breye Therapeutics Scientific Advisory Board, commented: “Danegaptide has the potential to become a valuable oral treatment option for patients with Diabetic Retinopathy. Patients should ideally be treated earlier and before the disease progresses to later stages, where laser treatments or intravitreally administered products are required.” 

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free